William Christie, MD
Ophthalmology · Cranberry Township, PANPI 1396747366
Payments from drug & device makers
Across 755 payments — averaging $6920.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3.6M
- Novartis$501K
- Ocular Therapeutix, Inc.$354K
- Johnson & Johnson Surgical Vision, Inc.$310K
- Glaukos Corporation$160K
- Bausch Health US, LLC$102K
- plus $177K from 19 others
Across 3 payments — averaging $10,792 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$31K
- Ocular Therapeutix, Inc.$1K
What the payments were for
- Consulting fees$3,35728%
- Travel & lodging$1962%
- Food & beverage$8,26569%
- Education$400%
- Other$1271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 439 | $3,621,036 |
| Novartis | 16 | $500,928 |
| Ocular Therapeutix, Inc. | 28 | $354,129 |
| Johnson & Johnson Surgical Vision, Inc. | 35 | $309,692 |
| Glaukos Corporation | 97 | $160,239 |
| Bausch Health US, LLC | 7 | $101,971 |
| Bausch & Lomb Americas Inc. | 21 | $72,655 |
| Alcon Research LLC | 7 | $56,432 |
| Aerie Pharmaceuticals, Inc. | 11 | $44,661 |
| Alcon | 39 | $1,194 |
| Tarsus Pharmaceuticals, Inc. | 13 | $594 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $464 |
| Sun Pharmaceutical Industries Inc. | 6 | $178 |
| Biotissue Holdings Inc. | 2 | $157 |
| Ivantis, Inc | 1 | $150 |
| Oyster Point Pharma, Inc. | 4 | $144 |
| Aesculap, Inc. | 1 | $127 |
| Sight Sciences, Inc. | 6 | $115 |
| Thea Pharma Inc. | 4 | $83 |
| Genentech USA, Inc. | 2 | $55 |
| Kala Pharmaceuticals, Inc. | 2 | $33 |
| Dompe US, Inc. | 2 | $32 |
| Rxsight Inc | 1 | $29 |
| Eyevance Pharmaceuticals LLC | 1 | $25 |
| Harrow Eye, LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis Symfony IOL$2,248
- enVista MX60 IOL$235
- DURYSTA$230
- XDEMVY$229
- VYZULTA$226
- Tecnis IOL$192
- Whitestar Signature$192
- DEXTENZA$186
- iDose TR$160
- Hydrus Microstent$150
- RESTASIS MULTIDOSE$150
- Centurion$148
- Prokera$142
- AmnioGraft$142
- AcrySof IQ VIVITY$141
- XEN GLAUCOMA TREATMENT SYSTEM$125
- PanOptix$124
- Rhopressa$117
- Rocklatan$117
- TRAVATAN Z$113
How this compares
$5,225,146 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 33 | $60,132 |
| RestasisCyclosporine | 28 | $39,854 |
| Cyclosporine | 37 | $24,500 |
| XiidraLifitegrast | 22 | $23,666 |
| VyzultaLatanoprostene Bunod | 28 | $14,655 |
| LumiganBimatoprost | 31 | $13,834 |
| Latanoprost | 500 | $7,952 |
| Alphagan PBrimonidine Tartrate | 15 | $6,948 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $4,880 |
| Prednisolone Acetate | 144 | $3,973 |
| Brimonidine Tartrate | 37 | $2,802 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 46 | $1,813 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 42 | $896 |
| Timolol Maleate | 23 | $476 |
| Ketorolac Tromethamine | 17 | $451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $3,621,036 | $65,51788 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $594 | $60,13233 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $72,655 | $38,32250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Cranberry Township
- Christopher SpearmanCranberry Township$659K
- David AlmeidaErie$6.3M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
- Brandon AyresBala Cynwyd$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.